Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Douglas Loe report not on tipranks yet

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon May 12, 2021 10:20am

274 Views

Post# 33182067

RE:Douglas Loe report not on tipranks yet

I get what you say about patience, and I know for some it is beyond trying. But I know what we have here, and the process a biotech has to go through, and the trials when new information is uncovered that affects MOA and research. This stock will change my life, so if I have to wait another year or two, so be it. My entire focus with ONC is the end game of Pelareorep.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?